Abstract
Severe acute respiratory syndrome coronavirus 2 principally weakens the hosts’ innate immune system by impairing the interferon function and production. Type I interferons (IFNs) especially IFN-β are best known for their antiviral activities. IFNs accompanied by the standard care protocols have opened up unique opportunities for treating the coronavirus disease 2019 (COVID-19). The databases including PubMed, SCOPUS, EMBASE, and Google Scholar were searched up to October 30, 2020. The primary and secondary outcomes were considered discharge and mortality, respectively. The abovementioned outcomes of standard care protocol were compared with the standard care plus IFN-β in the confirmed COVID-19 patients. Out of 356 records identified, 12 randomized clinical trial studies were selected for full-text screening. Finally, 5 papers were included in the systematic review and 3 papers in the meta-analysis. The average mortality rate was reported as 6.195% and 18.02% in intervention and control groups, respectively. Likewise, the median days of hospitalization were lower in the intervention group (9 days) than the control group (12.25 days). According to meta-analysis, IFN-β was found to increase the overall discharge rate (RR = 3.05; 95% CI: 1.09-5.01). Our findings revealed that early administration of IFN-β in combination with antiviral drugs is a promising therapeutic strategy against COVID-19.
Keywords: COVID-19; Discharge; Interferon-β; Review.
【저자키워드】 COVID-19, review, discharge, Interferon-β, 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, Meta-analysis, review, randomized clinical trial, Coronavirus disease 2019, coronavirus, protocol, Mortality, Hospitalization, antiviral drugs, interferons, interferon, systematic review, Intervention, outcome, severe acute respiratory syndrome Coronavirus, database, antiviral drug, innate immune system, databases, IFN, type I interferons, therapeutic strategy, IFNs, COVID-19 patients, Combination, Google Scholar, antiviral activities, acute respiratory syndrome, control group, intervention group, acute respiratory syndrome coronavirus, standard care, IFN-β, control groups, secondary outcome, confirmed COVID-19 patients, early administration, primary and secondary outcomes, discharge rate, Host, selected, reported, searched, unique, the interferon, Type, accompanied, average mortality, impairing, interferons (IFNs, the median, 【제목키워드】 clinical trial, offer,